Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre
Open Access
- 2 November 2011
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 23 (7), 1889-1893
- https://doi.org/10.1093/annonc/mdr520
Abstract
Febrile neutropenia (FN) is a potentially life-threatening complication following chemotherapy. The incidence and mortality of this condition varies according to cancer type and chemotherapy regimen. The aim of the study was to establish the incidence, risk, outcome, infectious cause and economic cost of FN in solid tumour patients within a routine oncology hospital setting. All FN solid tumour patients admitted to the oncology unit at a UK regional cancer centre were identified over a 12-month period. Demographic data on age, gender, cancer type, disease burden, chemotherapy regimen, antibiotic treatment, length of hospital stay and outcome was obtained. The annual incidence of FN was 19.4 per 1000 oncology admissions. The most common patient groups were those with breast (27%), lung (16%), ovarian (13%) and oesophageal (13%) cancers. The mean length of stay was 9.2 days with an average cost of £2353 for an FN episode per patient. The attributable mortality rate was 12.5%. The majority (83%) of patients who died were ≥60 years old, presented with hypotension and had a high-risk FN MASCC index compared with those that survived. This study demonstrates that FN in solid tumour patients continues to be associated with a significant morbidity and mortality during routine cancer care. Early risk classification of FN may help improve the outcome as well as reduce the economic burden.Keywords
This publication has 23 references indexed in Scilit:
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal Of Cancer, 2010
- Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practiceSupportive Care in Cancer, 2007
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer, 2006
- Chemotherapy‐induced neutropeniaCancer, 2004
- 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with CancerClinical Infectious Diseases, 2002
- The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer PatientsJournal of Clinical Oncology, 2000
- Science and pragmatism in the treatment and prevention of neutropenic infectionJournal of Antimicrobial Chemotherapy, 1998
- Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapyCancer, 1997
- A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patientsAnnals of Oncology, 1994
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaAnnals of Internal Medicine, 1966